@Biocartis_

Idylla™ ctKRAS Mutation Assay

 

Using liquid biopsies is minimally invasive, fast and easy to perform and provides an excellent solution to study the presence of KRAS mutations in different cancer types like colorectal cancer, pancreatic cancer and non-small cell lung cancer (NSCLC).

 

Discover the benefits of the Idylla™ ctKRAS Mutation Assay - the easiest solution to implement liquid biopsy testing in your research.

Highly standardized

 

The Idylla™ ctKRAS Mutation Assay, performed on the Biocartis Idylla™ System, is an assay for the qualitative detection of 21 mutations in codons 12, 13, 59, 61, 117, and 146 of the KRAS gene. The Idylla™ ctKRAS Mutation Assay extracts and amplifies KRAS circulating tumor DNA (ctDNA) from 1 ml of plasma. The Assay is a sample-to-result real-time PCR, intended to use for research applications only.

 

Idylla™ ctKRAS Mutation Assay is intended for Research Use Only.
Not for sale in the USA and Canada.

 

For product availability in your country contact us via customerservice@biocartis.com